Maxcyte (MXCT) Operating Leases (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Leases data on file, last reported at $16.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $16.1 million, down 8.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.1 million (down 8.17% YoY), and the FY2025 annual result was $16.5 million, down 3.98% from the prior year.
• Operating Leases retreated to $16.1 million in Q1 2026 per MXCT's latest filing, from $16.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $18.0 million in Q4 2023 and troughed at $12.8 million in Q1 2022.
• A 5-year average of $16.3 million and a median of $16.5 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2026: Operating Leases jumped 2873.17% in 2022, then slipped 8.17% in 2026.
• A 5-year view of Operating Leases shows it stood at $15.9 million in 2022, then rose by 12.74% to $18.0 million in 2023, then declined by 4.45% to $17.2 million in 2024, then decreased by 3.98% to $16.5 million in 2025, then decreased by 2.27% to $16.1 million in 2026.
• Business Quant data shows MXCT's Operating Leases at $16.1 million in Q1 2026, $16.5 million in Q4 2025, and $16.8 million in Q3 2025.